Appointment of Broker

Roquefort Therapeutics PLC

20 June 2024

 

20 June 2024

Roquefort Therapeutics plc

("Roquefort Therapeutics")

Appointment of Broker

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce the appointment of SP Angel Corporate Finance LLP as its broker with immediate effect.

-ENDS-

Enquiries:

Roquefort Therapeutics plc	[phone]
Stephen West (Chairman) / Ajan Reginald (CEO)
SP Angel Corporate Finance LLP (Broker) Jeff Keating / David Hignell / Vadim Alexandre	[phone]
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale	[phone]
Peak IR (Investor Relations) Seb Wykeham	[phone]

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.

Roquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines.  The highly complementary profile of five best-in-class medicines consists of:

·   Midkine antibodies with significant in vivo efficacy and toxicology studies;

·   Midkine RNA therapeutics with novel anti-cancer gene editing action;

·   Midkine mRNA therapeutics with novel anti-cancer approach;

·   STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and

·   MK cell therapy with direct and NK-mediated anti-cancer action

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).

 

END